XML 30 R19.htm IDEA: XBRL DOCUMENT v3.26.1
EPS Calculation
 6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
EPS Calculation EPS Calculation
 
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the three and six months ended June 30, 2026 and 2025:
 
Three Months Ended
June 30,		Six Months Ended
June 30,
(In Thousands, Except Per Share Amounts)2026202520262025
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders$46,798 $33,184 $45,814 $74,360 
Dividends declared on preferred stock(10,559)(10,560)(20,983)(18,779)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities(309)(200)(627)(406)
Net income/(loss) attributable to common stockholders - basic$35,930 $22,424 $24,204 $55,175 
Basic weighted average common shares outstanding103,674 103,705 103,962 103,740 
Basic Earnings/(Loss) per Share$0.35 $0.22 $0.23 $0.53 
Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic$35,930 $22,424 $24,204 $55,175 
Dividends, dividend equivalents and undistributed earnings allocated to participating securities— — — — 
Net income/(loss) attributable to common stockholders - diluted$35,930 $22,424 $24,204 $55,175 
Basic weighted average common shares outstanding103,674 103,705 103,962 103,740 
Unvested and vested restricted stock units1,764 1,602 1,691 1,536 
Diluted weighted average common shares outstanding (1)
105,438 105,307 105,653 105,276 
Diluted Earnings/(Loss) per Share$0.34 $0.21 $0.23 $0.52 
(1)At June 30, 2026 and 2025, the Company had approximately 1,021,000 and 931,000 equity instruments outstanding that were excluded from the calculation of diluted EPS for the three and six months ended June 30, 2026 and 2025, as they were determined to be anti-dilutive. These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $9.94 and $10.45, respectively. These equity instruments may have a dilutive impact on future EPS.